210 related articles for article (PubMed ID: 8393595)
1. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.
Boyle TJ; Berend KR; DiMaio JM; Coles RE; Via DF; Lyerly HK
Surgery; 1993 Aug; 114(2):218-25; discussion 226. PubMed ID: 8393595
[TBL] [Abstract][Full Text] [Related]
2. CD8high (CD57+) T cells in normal, healthy individuals specifically suppress the generation of cytotoxic T lymphocytes to Epstein-Barr virus-transformed B cell lines.
Wang EC; Lehner PJ; Graham S; Borysiewicz LK
Eur J Immunol; 1994 Nov; 24(11):2903-9. PubMed ID: 7525311
[TBL] [Abstract][Full Text] [Related]
3. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
Johannessen I; Bieleski L; Urquhart G; Watson SL; Wingate P; Haque T; Crawford DH
J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
[TBL] [Abstract][Full Text] [Related]
5. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
[TBL] [Abstract][Full Text] [Related]
6. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
[TBL] [Abstract][Full Text] [Related]
7. Generation of tumor-specific T lymphocytes for the treatment of posttransplant lymphoma.
DiMaio JM; Van Trigt P; Gaynor JW; Davis RD; Coveney E; Clary BM; Lyerly HK
Circulation; 1995 Nov; 92(9 Suppl):II202-5. PubMed ID: 7586409
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts.
Picchio GR; Kobayashi R; Kirven M; Baird SM; Kipps TJ; Mosier DE
Cancer Res; 1992 May; 52(9):2468-77. PubMed ID: 1314693
[TBL] [Abstract][Full Text] [Related]
9. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
[TBL] [Abstract][Full Text] [Related]
10. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma.
Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK
Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135
[TBL] [Abstract][Full Text] [Related]
12. Human cytotoxic T lymphocytes. III. Large numbers of peripheral blood T cells clonally develop into allorestricted anti-viral cytotoxic T cell populations in vitro.
Kabelitz D; Herzog WR; Heeg K; Wagner H; Reimann J
J Mol Cell Immunol; 1987; 3(1):49-60. PubMed ID: 2855406
[TBL] [Abstract][Full Text] [Related]
13. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
14. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma.
Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P
J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179
[TBL] [Abstract][Full Text] [Related]
15. [Molecular pathological characteristics of human B-cell lymphomas induced by Epstein-Barr virus].
Gan RL; Yin ZH; Liu TF; Dong BH; Zhou JG; Yao KT
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):925-9. PubMed ID: 14515211
[TBL] [Abstract][Full Text] [Related]
16. CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood.
Sun Q; Burton RL; Pollok KE; Emanuel DJ; Lucas KG
Cell Immunol; 1999 Aug; 195(2):81-8. PubMed ID: 10448007
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
[TBL] [Abstract][Full Text] [Related]
18. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
[TBL] [Abstract][Full Text] [Related]
19. Human-->mouse radiation chimera do not develop Epstein-Barr virus lymphoma.
Marcus H; Burakova T; Shezen E; David M; Canaan A; Lubin I; Reisner Y
Immunol Lett; 1996 Mar; 49(3):155-61. PubMed ID: 8739310
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
Lucas KG; Salzman D; Garcia A; Sun Q
Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
